The use of antimotility drugs in COVID-19 associated diarrhea

scientific article published on 18 September 2020

The use of antimotility drugs in COVID-19 associated diarrhea is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JINF.2020.09.017
P932PMC publication ID7501078
P698PubMed publication ID32956731

P2093author name stringSyed Shahzad Hasan
Chia Siang Kow
P2860cites workPutative Mechanisms of diarrhea in COVID-19Q96339450
Clinical and CT imaging features of SARS-CoV-2 patients presented with diarrheaQ98243998
Loperamide therapy for acute diarrhea in children: systematic review and meta-analysisQ21144674
Hemolytic-uremic syndrome and enterohemorrhagic Escherichia coliQ33492019
Adverse Effect of Lomotil Therapy in ShigellosisQ34213819
Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homesQ43245166
A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adultsQ44069777
P921main subjectCOVID-19Q84263196
P577publication date2020-09-18
P1433published inJournal of InfectionQ6295344
P1476titleThe use of antimotility drugs in COVID-19 associated diarrhea

Search more.